RT Journal Article SR Electronic T1 Low Dihydropyrimidine Dehydrogenase Correlates with Prolonged Survival in Patients with Lung Adenocarcinoma Treated with 5-Fluorouracil JF Anticancer Research JO Anticancer Res FD International Institute of Anticancer Research SP 4665 OP 4671 VO 31 IS 12 A1 YASUSHI SHINTANI A1 MASAYOSHI INOUE A1 YASUNOBU FUNAKOSHI A1 AKIHIDE MATSUMURA A1 MITSUNORI OHTA A1 HAJIME MAEDA A1 MEINOSHIN OKUMURA YR 2011 UL http://ar.iiarjournals.org/content/31/12/4665.abstract AB Background: The enzyme dihydropyrimidine dehydrogenase (DPD) is involved in the metabolism of 5-fluorouracil (5-FU). The aim of this study was to clarify the correlation between the expression of DPD and the efficacy of 5-FU therapy in patients with lung adenocarcinoma (AD). Patients and Methods: We examined surgically resected specimens from 90 stage I to IIIA patients with lung ADs to determine the level of intra-tumoral DPD mRNA. Results: Administration of 5-FU improved the prognosis of patients with low DPD-expressing tumors, whereas it did not do so for patients with high DPD expressing tumors. Patients with low DPD-expressing tumors administered with 5-FU had a significantly better prognosis than those who underwent surgery alone. A Cox proportional hazards regression model revealed that administration of 5-FU was an independent variable to predict prognosis in patients with low DPD-expressing tumors. Conclusion: Quantification of DPD mRNA levels is useful for determining the subgroup of lung AD patients who would benefit most from 5-FU after surgery.